In vitro dose-response comparison of [177Lu]Lu-labelled somatostatin receptor agonist and antagonist

Research output: Contribution to report/book/conference proceedingsIn-proceedings paperpeer-review


Institutes & Expert groups

  • Erasmus MC

Documents & links


Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin receptor (SST) is very effective for treatment of neuroendocrine metastatic tumors. Recent studies indicate that radiolabeled SST antagonists show better tumor targeting during clinical imaging and preclinical therapy, despite little to no internalization in the cancer cells. However, preclinical studies are often limited to activity uptake, with no correlation between the delivered absorbed dose and the biological end-point. This study aims to calculate the absorbed dose to the nucleus for [177Lu]Lu-DOTA-Tyr3,octreotate (177Lu-DOTA-TATE, SST agonist) and [177Lu]Lu-DOTA-JR11 (177Lu- DOTA-JR11, SST antagonist), for comparison with DNA damage induction.


Original languageEnglish
Title of host publicationAnnual Congress of the European Association of Nuclear Medicine October 12 – 16, 2019 Barcelona, Spain
Subtitle of host publicationEuropean Journal of Nuclear Medicine and Molecular Imaging volume
Number of pages2
Publication statusPublished - 16 Oct 2019


  • Double strand breaks, Targeted Radionuclide Therapy, Dose-response

ID: 6743654